^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA® TROP2 (EPR20043) RxDx Assay

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    7ms
    Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer (Roche Press Release)
    "The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment; The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods; This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology."
    FDA event
    |
    VENTANA® TROP2 (EPR20043) RxDx Assay